Photo from wikipedia
The development of an anti‐FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients. The current management of haemophilia A with… Click to show full abstract
The development of an anti‐FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients. The current management of haemophilia A with inhibitor uses bypassing agents (BPA) and represents a significant therapeutic burden together with a limited adherence to prophylactic treatment. Emicizumab is the first monoclonal antibody developed in haemophilia A approved for the prevention of bleeding episodes in patients with anti‐FVIII inhibitor.
Keywords:
bleeding episodes;
patients anti;
prevention bleeding;
anti fviii;
bypassing agents
Journal Title: Haemophilia
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!